TY - JOUR
T1 - Subjective recognition of adverse events with antidepressant in people with depression
T2 - A prospective study
AU - Kikuchi, Toshiaki
AU - Suzuki, Takefumi
AU - Uchida, Hiroyuki
AU - Watanabe, Koichiro
AU - Kashima, Haruo
N1 - Funding Information:
Dr. Kikuchi has received manuscript fees or speaker's honoraria from Astellas Pharma, Dainippon Sumitomo Pharma, GlaxoSmithKline, Jansen Pharmaceutical, Otsuka Pharmaceutical, Pfizer, Shionogi and Yoshitomiyakuhin within the past 5 years. Dr. Suzuki has received grants from the Japanese Society of Clinical Neuropsychopharmacology, Government of Canada Postdoctoral Research Fellowships, Kanae Foundation and Mochida Memorial Foundation, and manuscript fees from Dainippon Sumitomo Pharma and Kyowa Hakko Kirin within the past 5 years. Dr. Uchida has received grants, speaker's honoraria, or manuscript fees from GlaxoSmithKline, Otsuka Pharmaceutical, Dainippon Sumitomo Pharma, Janssen Pharmaceutical, and Pfizer within the past 5 years. Dr. Watanabe has received consultant fees, manuscript fees, research supports or speaker's honoraria from Astellas Pharma, Dainippon Sumitomo Pharma, Eli Lilly, GlaxoSmithKline, Jansen Pharmaceutical, Otsuka Pharmaceutical, Pfizer, Meiji and Yoshitomiyakuhin within the past 5 years. Dr. Kashima has nothing to disclose.
PY - 2011/12
Y1 - 2011/12
N2 - Background: While it has been reported that physicians may under-recognize adverse effects of antidepressants thoroughly in clinical settings, subjective bias in recognition of adverse effects (AEs) with antidepressants has not been specifically investigated. Methods: Four-hundred ninety-three participants with depressive disorders (ICD-10) were assessed for the severity of 20 common AEs and their inferred causal relationship with antidepressants, together with the Quick Inventory for Depressive Symptoms (QIDS). These assessments occurred twice at the 1st visit (when they were antidepressant free) and 2nd visit (10 days after the initiation of antidepressants). 'Possible AEs' and 'under-recognized AEs' were defined as 'events with exacerbation in the severity' and 'events with negative causal attribution to antidepressants' at the time of the 2nd visit, respectively. Results: Three-hundred sixty-three participants (73.6%) experienced ≥1 under-recognized AEs. Flu like symptoms (96.5% of participants who experienced possible AEs), sexual dysfunction (94.2%), blurred vision (93.4%), anxiety/tension (91.1%) and sweating (89.2%) were found to be prevalent as under-recognized AEs. Participants with under-recognized AEs had less improvement in the QIDS than those without (27.1% vs. 11.1% decrease, p < 0.001). Limitations: It is intrinsically challenging to exactly differentiate between antidepressant AEs and symptoms of depression. And the severity of depression, that of AEs and causal relationship between AEs and antidepressants were assessed not by objective but subjective scales. Conclusions: An overall trend to under-recognize AEs of antidepressants was found and people with a lesser degree of early improvement tend to understate the causality, which has an implication in interpreting voluntarily expression of AEs.
AB - Background: While it has been reported that physicians may under-recognize adverse effects of antidepressants thoroughly in clinical settings, subjective bias in recognition of adverse effects (AEs) with antidepressants has not been specifically investigated. Methods: Four-hundred ninety-three participants with depressive disorders (ICD-10) were assessed for the severity of 20 common AEs and their inferred causal relationship with antidepressants, together with the Quick Inventory for Depressive Symptoms (QIDS). These assessments occurred twice at the 1st visit (when they were antidepressant free) and 2nd visit (10 days after the initiation of antidepressants). 'Possible AEs' and 'under-recognized AEs' were defined as 'events with exacerbation in the severity' and 'events with negative causal attribution to antidepressants' at the time of the 2nd visit, respectively. Results: Three-hundred sixty-three participants (73.6%) experienced ≥1 under-recognized AEs. Flu like symptoms (96.5% of participants who experienced possible AEs), sexual dysfunction (94.2%), blurred vision (93.4%), anxiety/tension (91.1%) and sweating (89.2%) were found to be prevalent as under-recognized AEs. Participants with under-recognized AEs had less improvement in the QIDS than those without (27.1% vs. 11.1% decrease, p < 0.001). Limitations: It is intrinsically challenging to exactly differentiate between antidepressant AEs and symptoms of depression. And the severity of depression, that of AEs and causal relationship between AEs and antidepressants were assessed not by objective but subjective scales. Conclusions: An overall trend to under-recognize AEs of antidepressants was found and people with a lesser degree of early improvement tend to understate the causality, which has an implication in interpreting voluntarily expression of AEs.
KW - Adverse effects
KW - Antidepressant
KW - Depression
KW - Subjective recognition
KW - Under-recognition
UR - http://www.scopus.com/inward/record.url?scp=80055018406&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80055018406&partnerID=8YFLogxK
U2 - 10.1016/j.jad.2011.07.011
DO - 10.1016/j.jad.2011.07.011
M3 - Article
C2 - 21821295
AN - SCOPUS:80055018406
SN - 0165-0327
VL - 135
SP - 347
EP - 353
JO - Journal of Affective Disorders
JF - Journal of Affective Disorders
IS - 1-3
ER -